ArticleClinical rheumatology2026
Burden of osteoarthritis in North Africa and Middle East from 1990 to 2021: findings from the Global Burden of Disease 2021 study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Human BMP4 mRNA Encapsulated in Lipid Nanoparticle for Bone and Articular Cartilage Repair in Aged Mice.Journal of functional biomaterials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo quantify the burden of osteoarthritis (OA) and give an account of the most recent data on incidence, prevalence, and years lived with disability (YLDs) of OA for the North Africa and Middle East (NAME) region over time with a particular focus on changes from 1990 to 2021.
methodIn this epidemiological study, data from the Global Burden of Disease 2021 study were used. The prevalence, incidence, and YLDs of OA were obtained for both sexes in 21 countries of the NAME region. These estimates are reported in the form of all-age numbers and age-standardized rates, together with their 95% uncertainty intervals (UIs).
resultThe all-age numbers of incidence, prevalence, and YLDs in 2021 were about 2.7 million (95% UIs, 2.4 to 3.0), 30.5 million (27.1 to 33.7), and 1.0 million (0.5 to 2.1). From 1990 to 2021, the burden of OA was higher in females than in males, and the rates of prevalence and YLDs increased as age rose. However, the rate of incidence increased until the ages 60-64 and then decreased. Kuwait had the highest burden, whereas Afghanistan had the lowest burden. The highest burden among OA subgroups was related to knee OA, while hip OA had the least attributable burden. Overall, the burden of OA had a direct association with the sociodemographic index (SDI).
conclusionIn summary, the prevalence, incidence, and YLD rates of osteoarthritis have shown an upward trend across most countries. The disease is positively associated with female sex, age, and SDI, implementing targeted medical prevention and treatment interventions in high-SDI countries. Key Points • This study presents a comprehensive analysis of the burden of osteoarthritis in North Africa and the Middle East from 1990 to 2021 using data from the Global Burden of Disease 2021 study. The findings highlight regional trends in osteoarthritis incidence, prevalence, and years lived with disability, offering valuable insights into healthcare planning and policy development.
Indexed as
Identifiers
41307626What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.